Showing 521-530 of 618 results for "".
- Aramis Biosciences Receives FDA Clearance to Proceed with Phase 2 Trail of A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-receives-fda-clearance-to-proceed-with-phase-2-trail-of-a197-a-novel-immunomodulatory-agent-for-the-treatment-of-dry-eye-disease/2480558/Aramis Biosciences announced that the FDA has cleared the investigational new drug (IND) application for A197, enabling the company to proceed with a phase 2 proof of concept clinical trial. “We are pleased that FDA has cleared A197 to move into phase 2 clinica
- Can Ophthalmic Clinical Trials Proceed During COVID-19 Crisis?https://modernod.com/news/covid-19-can-clinical-trials-proceed/2477676/
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Novartis to Sell Roche Stake for $20.7 Billionhttps://modernod.com/news/novartis-to-sell-roche-stake-for-207-billion/2480406/Novartis said Thursday that it agreed to sell its stake in Roche for $20.7 billion, with the proceeds to be used "in line with capital allocation priorities to enhance strong returns to shareholders," according to a FirstWord repor
- Gyroscope Therapeutics Announces $148 Million Raised in Series C Financinghttps://modernod.com/news/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/2479018/Gyroscope Therapeutics announced it has raised $148.0 million (£107.8 million) in a Series C financing. Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005,
- Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopiahttps://modernod.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/Orasis Pharmaceuticals announced the closing of a $30 million Series C financing. Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia sympto
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St
- Alcon Receives Health Canada Approval for Unity VCShttps://modernod.com/news/alcons-receives-health-canada-approval-for-unity-vcs/2482882/Alcon announced that Unity Vitreoretinal Cataract System (VCS) has received Health Canada approval. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon’s current leading systems, Constellation Vision System for vitreoretinal and combined proce
- LambdaVision Closing of Seed Round to Advance Artificial Retina Preclinical Studieshttps://modernod.com/news/lambdavision-closing-of-seed-round-to-advance-artificial-retina-preclinical-studies/2482302/LambdaVision, which is developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round. The proceeds will be used to fund LambdaVision’s GMP manufacturing scale up and critical IN
- ViaLase Closes $40 million Series C Financing to Advance First Femtosecond Laser for the Treatment of Glaucomahttps://modernod.com/news/vialase-closes-40-million-series-c-financing-to-advance-first-femtosecond-laser-for-the-treatment-of-glaucoma/2482192/ViaLase has closed a Series C financing with proceeds of approximately $40 million to continue advancement of clinical, regulatory, and commercial milestones of the company's ViaLase Laser. If approved, the ViaLase Laser will be the first femtosecond laser used for the tre